alpha 1-adrenergic receptor

临床试验

计划入组 5 人 · 首次发布于 2020 年 4 月 28 日

已完成

NCT00730418

Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia

计划入组 25 人 · 首次发布于 2008 年 8 月 8 日

招募中

NCT07174349

Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

计划入组 20 人 · 首次发布于 2025 年 9 月 15 日

药物

查看全部 8939 →

Small Molecule

Approved

Silodosin(Rapaflo, Silodyx, Urorec, Silodosin Recordati)

相关疾病：Benign Prostatic Hyperplasia (BPH)

C₂₅H₃₂F₃N₃O₄ · Rx

Small Molecule

Approved

Doxazosin(Cardura)

生产企业：Pfizer inc, Pfizer laboratories div pfizer inc，另有 11 家

相关疾病：Benign Prostatic Hyperplasia (BPH), Hypertension，另有 1 项

C₂₃H₂₅N₅O₅ · Rx

OKG-0301 + alpha adrenergic receptor agonist

机构

查看全部 1423 →

ALPHA-1 FOUNDATION, INC.

United States

Arvinas Estrogen Receptor, Inc.

United States

NHI-1

United States

资讯

查看全部 17383 →

2年前

FDA Approves Ryzumvi for Treating Drug-Induced Mydriasis

11个月前

World's Largest Parkinson's Clinical Trial Platform Launches in UK, Testing Multiple Disease-Modifying Therapies Simultaneously

去年

临床试验

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia

Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

药物

Silodosin(Rapaflo, Silodyx, Urorec, Silodosin Recordati)

Doxazosin(Cardura)

OKG-0301 + alpha adrenergic receptor agonist

机构

ALPHA-1 FOUNDATION, INC.

Arvinas Estrogen Receptor, Inc.

NHI-1

资讯

FDA Approves Ryzumvi for Treating Drug-Induced Mydriasis

World's Largest Parkinson's Clinical Trial Platform Launches in UK, Testing Multiple Disease-Modifying Therapies Simultaneously

European Commission Approves AbbVie's Elahere for Folate Receptor-Alpha Positive Ovarian Cancer